KR20170125927A - 골밀도의 조절 방법 - Google Patents

골밀도의 조절 방법 Download PDF

Info

Publication number
KR20170125927A
KR20170125927A KR1020177027942A KR20177027942A KR20170125927A KR 20170125927 A KR20170125927 A KR 20170125927A KR 1020177027942 A KR1020177027942 A KR 1020177027942A KR 20177027942 A KR20177027942 A KR 20177027942A KR 20170125927 A KR20170125927 A KR 20170125927A
Authority
KR
South Korea
Prior art keywords
disease
compound
hydrogen
subject
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177027942A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 샤피로
아도리니 루치아노
Original Assignee
인터셉트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인터셉트 파마슈티컬즈, 인크. filed Critical 인터셉트 파마슈티컬즈, 인크.
Publication of KR20170125927A publication Critical patent/KR20170125927A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177027942A 2015-03-09 2016-03-08 골밀도의 조절 방법 Withdrawn KR20170125927A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130144P 2015-03-09 2015-03-09
US62/130,144 2015-03-09
PCT/US2016/021344 WO2016144946A1 (en) 2015-03-09 2016-03-08 Methods for modulating bone density

Publications (1)

Publication Number Publication Date
KR20170125927A true KR20170125927A (ko) 2017-11-15

Family

ID=56879295

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177027942A Withdrawn KR20170125927A (ko) 2015-03-09 2016-03-08 골밀도의 조절 방법

Country Status (12)

Country Link
US (1) US20180042943A1 (enExample)
EP (1) EP3268009A4 (enExample)
JP (1) JP2018507880A (enExample)
KR (1) KR20170125927A (enExample)
CN (1) CN107530361A (enExample)
AU (1) AU2016229906A1 (enExample)
CA (1) CA2978916A1 (enExample)
HK (1) HK1243646A1 (enExample)
IL (1) IL254197A0 (enExample)
MX (1) MX2017011399A (enExample)
SG (1) SG11201707328SA (enExample)
WO (1) WO2016144946A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US10919162B2 (en) 2018-12-26 2021-02-16 Ford Global Technologies, Llc Systems and methods for efficient power management of modular mobile robot platforms with replaceable batteries
DE102020101118A1 (de) 2019-01-18 2020-07-23 Ford Global Technologies, Llc Mobile mehrzweckroboter und verfahren zu deren verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223214B2 (en) * 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003080803A2 (en) * 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
JP2012072095A (ja) * 2010-09-29 2012-04-12 Tokyo Institute Of Technology 骨形成促進剤
ES2822375T3 (es) * 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
WO2014021694A1 (ko) * 2012-08-03 2014-02-06 서울대학교 산학협력단 골 관련 질환 예방 및 치료를 위한 조성물
HRP20180931T1 (hr) * 2013-05-14 2018-10-05 Intercept Pharmaceuticals, Inc. 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x

Also Published As

Publication number Publication date
AU2016229906A1 (en) 2017-09-21
CA2978916A1 (en) 2016-09-15
US20180042943A1 (en) 2018-02-15
HK1243646A1 (zh) 2018-07-20
JP2018507880A (ja) 2018-03-22
WO2016144946A1 (en) 2016-09-15
SG11201707328SA (en) 2017-10-30
MX2017011399A (es) 2018-03-16
IL254197A0 (en) 2017-10-31
CN107530361A (zh) 2018-01-02
EP3268009A4 (en) 2018-12-12
EP3268009A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
US10576091B2 (en) Tomatidine, analogs thereof, compositions comprising same, and uses for same
CN1759834B (zh) 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US12310935B2 (en) Methods of treatment of cholestatic diseases
WO2018148417A1 (en) Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
US20230190743A1 (en) Treatment with ileal bile acid transporter (ibat) inhibitors for increased event-free survival (efs)
US20220265614A1 (en) Treatment comprising fxr agonists
KR20170125927A (ko) 골밀도의 조절 방법
JP7079735B2 (ja) 肝内胆汁うっ滞性疾患の処置
CN109562108A (zh) 用于治疗与c反应蛋白相关的疾病的1-甲基烟酰胺
US11179364B2 (en) Licofligozin for the treatment of non-alcoholic steatohepatitis
Qiu et al. Geniposide dosage and administration time: balancing therapeutic benefits and adverse reactions in liver disease treatment
CN109806250A (zh) 一种含羟基脲的药物组合物的应用
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
BR112021003265A2 (pt) métodos para reduzir o risco de diabetes em pacientes sendo tratados para doenças relacionadas a colesterol alto
US12377104B1 (en) Methods for treating a fatty liver disease
US20250161326A1 (en) Combination therapy
WO2025250918A1 (en) Novel compositions
CN113226374B (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
Dzierwa et al. Eosinophilic myocarditis: Gardia lamblia infestation and Garcinia cambogia. Coincidence or causality?(RCD code: III‑1B. 1. o)
JP7048863B2 (ja) 非アルコール性脂肪肝疾患の治療法
EP4658275A1 (en) Methods for treating a fatty liver disease
Cramb et al. UK consensus position on the management of homozygous familial hypercholesterolaemia and the introduction of new agents
Korzeniowska et al. Metformin-induced diarrhea–case report Biegunka wywołana metforminą–opis przypadku
HK40008997A (en) Inhibition of fibrosis in non-alcoholic fatty liver disease patients

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170929

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination